Equities analysts predict that Repligen Co. (NASDAQ:RGEN) will report earnings of $0.20 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Repligen’s earnings, with the lowest EPS estimate coming in at $0.18 and the highest estimate coming in at $0.21. Repligen reported earnings per share of $0.17 during the same quarter last year, which suggests a positive year over year growth rate of 17.6%. The firm is expected to announce its next earnings results on Tuesday, May 14th.

On average, analysts expect that Repligen will report full-year earnings of $0.83 per share for the current fiscal year, with EPS estimates ranging from $0.81 to $0.84. For the next year, analysts anticipate that the firm will report earnings of $1.00 per share, with EPS estimates ranging from $0.97 to $1.05. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Repligen.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.21. Repligen had a return on equity of 5.51% and a net margin of 8.56%. The business had revenue of $51.90 million for the quarter, compared to the consensus estimate of $50.27 million. During the same quarter in the previous year, the company posted $0.20 earnings per share. Repligen’s revenue for the quarter was up 24.8% compared to the same quarter last year.

A number of research analysts have commented on the company. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $69.00 target price on the stock in a research note on Thursday, December 13th. CL King upgraded Repligen from a “neutral” rating to a “buy” rating in a research note on Monday, December 17th. They noted that the move was a valuation call. Finally, BidaskClub downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Repligen has an average rating of “Buy” and an average target price of $59.20.

In other Repligen news, CEO Anthony Hunt sold 13,000 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $58.50, for a total value of $760,500.00. Following the completion of the sale, the chief executive officer now owns 229,657 shares of the company’s stock, valued at $13,434,934.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jon Snodgres sold 1,875 shares of the business’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $58.88, for a total value of $110,400.00. Following the completion of the sale, the chief financial officer now directly owns 26,821 shares of the company’s stock, valued at approximately $1,579,220.48. The disclosure for this sale can be found here. Insiders sold 48,437 shares of company stock worth $2,855,032 in the last 90 days. Corporate insiders own 1.40% of the company’s stock.

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its position in shares of Repligen by 10.8% in the fourth quarter. Geode Capital Management LLC now owns 453,699 shares of the biotechnology company’s stock worth $23,927,000 after buying an additional 44,186 shares during the last quarter. Norges Bank acquired a new stake in shares of Repligen in the fourth quarter worth about $18,352,000. Advisory Services Network LLC lifted its position in shares of Repligen by 10.7% in the fourth quarter. Advisory Services Network LLC now owns 1,771 shares of the biotechnology company’s stock worth $93,000 after buying an additional 171 shares during the last quarter. Amalgamated Bank acquired a new stake in shares of Repligen in the fourth quarter worth about $324,000. Finally, Millennium Management LLC acquired a new stake in shares of Repligen in the fourth quarter worth about $11,021,000. 90.96% of the stock is owned by institutional investors.

Shares of RGEN stock traded down $1.79 on Wednesday, reaching $57.42. 456,206 shares of the company’s stock traded hands, compared to its average volume of 303,495. Repligen has a 12-month low of $34.16 and a 12-month high of $70.50. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of 78.66, a P/E/G ratio of 4.06 and a beta of 1.09.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Story: What are earnings reports?

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.